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Background:  DBS  testing  has  been  used  successfully  to  detect  HCV  antibody  positive  individuals.  Deter-
mining  how  long  someone  has been  infected  is  important  for surveillance  initiatives.  Antibody  avidity  is
a method  that  can  be used  to  calculate  recency  of  infection.
Objectives:  A  HCV  avidity  assay  was  evaluated  for both  plasma  and  DBS.
Study design:  To  measure  antibody  avidity  a commercial  HCV  ELISA  was  modiﬁed  using  7 M urea.  The
plasma  samples  were  split  into:  group  1 (recently  infected  N  = 19),  group  2 (chronic  carrier  N =  300)  and
group  3  (resolved  infection  N  = 82).  Mock  DBS  made  from  group  1  (N = 12),  group  2  (N =  50),  group  3
(N  =  25)  and two  seroconverter  panels  were  evaluated.  133  DBS  taken  from  patients  known  to have a
resolved  infection  or be  a chronic  carrier  were  also  tested.
Results:  The  avidity  assay  cut-off  was  set at  AI  ≤  30 for a recent  infection.  Using  sequential  samples  the
assay could  detect  a recent  infection  in  the ﬁrst 4–5  months  from  the  point  of infection.  Most  of the
false  positive  results  (AI  < 30  among  cases  known  not  to  have  had  recent  infection)  were  detected  among
known  resolved  infections,  in  both  the  plasma  and  DBS;  as  a result,  a  testing  algorithm  has been  designed
incorporating  both  PCR  and  two  dilution  factors.  The  sensitivity  and  speciﬁcity  of the  assay  on  plasma
was 100%  and  99.3%,  respectively,  while  DBS  had 100%  sensitivity  and  98.3%  speciﬁcity.
Conclusion:  The  HCV  avidity  assay  can be used  to distinguish  between  chronic  and  recent  infection  using
either  plasma  or  DBS  as the sample  type.
© 2013 Elsevier B.V. All rights reserved.
1. Background
In Scotland, approximately 1% of the population are hepatitis
C virus (HCV) antibody (anti-HCV) positive and a signiﬁcant pro-
portion acquired infection through injecting drug use.1 It can be
difﬁcult to obtain a conventional blood sample from people who
inject drugs (PWID) and dried blood spot (DBS) testing is a non-
invasive method that can be used for antibody and PCR testing.2–4
In specialist drug service settings in Scotland, it has contributed
greatly to the rise in the number of HCV diagnoses.1 DBS testing
has also been used successfully for surveillance purposes.5–7
Treatment of early HCV infection is associated with higher
sustained virological response rates, including among PWID.8–10
The ability to distinguish between a recently acquired and a past
∗ Corresponding author at: West of Scotland Specialist Virology Centre, Gartnavel
General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom.
Tel.: +44 141 2110080.
E-mail address: Samantha.Shepherd@ggc.scot.nhs.uk (S.J. Shepherd).
infection is important to help guide the clinical management of
patients with HCV and direct prevention initiatives.6
A recently acquired HCV infection is often asymptomatic.10 Tra-
ditionally a recent HCV infection is determined by monitoring
antibody IgG seroconversion, and/or the detection of viral RNA in
the absence of anti-HCV. It can take between 1–4 weeks for RNA
and 8–12 months for antibody to become detected after infection
with HCV.11 The presence of anti-HCV and HCV PCR can indicate
either an acute or a chronic infection, even in the presence of ele-
vated liver function tests.11 IgM antibody in HCV can be detected
during exacerbation of chronic HCV.12 An anti-HCV positive and
PCR negative result usually indicates a resolved HCV infection, but
can also indicate an acute infection with low viraemia.11
Antibody avidity is the binding capacity of maturing antibody
with antigen, which increases over time. A dissociation agent (DA)
can remove weakly bound antibody.13 The avidity index (AI) can be
measured using a modiﬁed enzyme linked immunoassay (ELISA)
by comparing an untreated sample and one treated with the DA.14
Antibodies generated early in infection have weak antigen-binding
capacity compared to a matured antibody generated against the
1386-6532/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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Table 1
Characteristics of the patient groups used in this study.
Patient group Number of
samples
Average age
(range)
Average anti-HCV
(range)
Average viral load
IU/ml
(range)
Number of patients with each genotype
1 2 3 4 NT
Group 1 (recent)
plasma/serum
19 34(20–62) 9.54
(5.65–16.09)
2,436,152a
(948–16,900,000)
7 3 5 0 4
Group 1 (recent)
mock DBS
12 34(20–61) 10.83
(5.65–16.09)
132,671
(948–384,518)
3 3 3 0 3
Group 2 (chronic)
plasma/serum
300 42(5–77) 12.93
(6.35–17.97)
1,178,851b
(1280–9,760,000)
152 14 108 2 24
Group 2 (chronic)
mock DBS
50 42(22–70) 12.51
(8.89–15.15)
1,007,687c
(3686–8,330,000)
25 3 17 2 3
Group 3 (resolved)
plasma/serum
82 39(23–60) 10.86
(3.17–17.14)
N/A
Group 3 (resolved)
mock DBS
25 42(25–60) 11.79
(6.13–14.92)
N/A
Group 4 (chronic)
patient DBS
65 39(23–74) >3d PCR qualitative
only
65e
Group 5 (resolved)
patient DBS
68 37(25–60) >3 for 36 samples
1.78 (0.89–2.99) for
42 samples
N/A
a 4 samples were tested by a qualitative PCR method, 2 samples tested by Abbott Architect HCV core assay and 2 patients had a viral load < 1000 IU/ml  (limit of detection
of  the HCV PCR was  50 IU/ml).
b 33 chronic patients had a viral load < 1000 IU/ml (limit of detection of the HCV PCR was  50 IU/ml).
c 6 chronic patients had a viral load < 1000 IU/ml (limit of detection of the HCV PCR was  50 IU/ml).
d Anti-HCV assay for DBS is the Ortho manual ELISA (see study design). Any sample with an OD > 0.8 is considered positive. All samples had an OD of >3 with the exception
of  one sample (OD = 1.980).
e HCV genotype is not currently tested on DBS.
same antigen. Several papers have addressed HCV avidity testing
but all have been described using plasma/serum samples.15–19 All
the HCV avidity methods reported are modiﬁcations of commercial
or in house ELISA kits using either guanidine or urea as the DA. The
method described in this paper uses a modiﬁed commercial assay
with an overnight incubation stage for HCV avidity testing. This
assay can be used for both plasma/serum and DBS. To the best of
our knowledge HCV avidity has not been reported using DBS.
2. Objectives
The aim of this study was to evaluate a HCV avidity test on
plasma/serum and DBS for use in a routine laboratory as both a
diagnostic and epidemiological surveillance tool.
3. Study design
3.1. Plasma and serum samples
Plasma or serum samples sent to the West of Scotland Spe-
cialist Virology Centre (WoSSVC) for routine anti-HCV and HCV
PCR testing which had been stored at −80 ◦C were used in this
study. All plasma/serum samples were screened for anti-HCV by
the Abbott Architect Anti-HCV assay. The samples to be tested
were grouped into recent, chronic and resolved infections (Table 1).
Group 1 consisted of 19 patients samples with a recent HCV infec-
tion, deﬁned as having either an anti-HCV positive result within (a)
4–6 months of a previous anti-HCV negative result, or (b) within 1
month of a previous anti-HCV negative and PCR positive result. All
of group 1 were HCV PCR positive. Two of the patients within group
1 were renal patients involved in a HCV outbreak. These 2 patients
had 8 and 5 follow up samples taken sequentially over a 5 and 6
month period, respectively. Three other patients within group 1 had
a follow up sample. Group 2 consisted of 300 patients with chronic
HCV, deﬁned as those who tested anti-HCV and HCV PCR posi-
tive for greater than 1 year. Group 3 consisted of 82 patients with
resolved HCV infection, deﬁned as those who had tested anti-HCV
positive and HCV PCR negative for an average of 6 years (range 1–14
years). Information on the number of patients treated, the duration
of HCV infection or if HCV reinfection occurred was  unknown for
both groups 2 and 3.
Two seroconvertor panels PHV901 (N = 10) and PHV917 (N = 9)
were obtained from AlereTM (Cheshire, UK), the genotypes for the
panels were 1a and 2b, respectively.
3.2. Mock DBS
HCV negative whole blood was  centrifuged in 200 l aliquots
at 5000 rpm for 5 min, after which 60 l of plasma was removed
and replaced by 60 l of known HCV positive plasma. The samples
were re-suspended and 50 l was then spotted onto Whatman 903
Protein Saver cards and allowed to dry at room temperature for over
1 h. Twelve of the samples from group 1, 50 samples from group 2,
25 samples from group 3 and seroconvertor panels PHV901 and
PHV917 were made into mock DBS samples. The DBS were stored
at 4 ◦C until use.
3.3. Patient DBS samples
DBS sent to the WoSSVC for anti-HCV and HCV PCR test-
ing and subsequently stored at 4 ◦C were used in this study.
The samples came from clinics run by community addition ser-
vices. Group 4 consisted of 65 DBS taken from known chronic
patients (tested anti-HCV and HCV PCR positive for >1 year)
and group 5 consisted of 68 DBS from resolved patients (tested
anti-HCV and HCV PCR negative for an average of 6 years,
range 1–14). The patients chosen for each group had had pre-
vious HCV results from plasma samples on record at WoSSVC.
Information on the number of patients treated and the dura-
tion of HCV infection was unknown for both groups 4 and
5.
3.4. HCV antibody testing of DBS
The ORTHO HCV 3.0 ELISA Test System with Enhanced SAVekit
(Ortho Clinical Diagnostics) was used to detect anti-HCV in DBS
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Fig. 1. Diagram indicating how the DBS dilution factors used in the avidity assay was  calculated.
using a modiﬁed version of the Judd et al4 method. The modiﬁcation
was two 3 mm discs punched from the DBS and eluted in 200 l of
PBS/0.05% Tween.
3.5. Avidity assay
The avidity assay is a modiﬁcation of the ORTHO HCV 3.0 ELISA
Test System with Enhanced SAVekit (Ortho Clinical Diagnostics).
Plasma samples were diluted either 1/100 or 1/400 in kit dilu-
ent and 200 l was added to 2 wells of a 96 well plate. The plate
was shaken overnight at room temperature. The samples were
washed once to remove unbound material. One sample was  washed
in 300 l kit buffer while the duplicate sample was washed with
300 l 7 M urea (dissolved in kit buffer). This was done three times
for 5 min. The microtitre plate was washed seven times. Note that
all washes were in 300 l of kit wash buffer. 200 l of conjugate
was added for 3 h and the plate was then washed six times. The
manufacturers’ guidelines were then followed for the remaining
steps. The AI was calculated by taking the optical density (OD) of
the urea treated specimen divided by the OD of the wash buffer
treated sample and expressed as a percentage. The OD was  mea-
sured using the plate reader function on the Siemens BEP III. To
calculate the AI, samples treated with wash buffer should have an
OD > 1.0.
The avidity assay described above was used for DBS with the
following modiﬁcation 20 l eluted DBS was added to 110 l kit
diluent or 65 l eluted DBS was added to 65 l kit diluent, this
resulted in a ﬁnal dilution factor of either 1/240 or 1/74 which cor-
responded to a plasma dilution of 1/432 and 1/133, respectively
(Fig. 1).
3.6. HCV RNA extraction and ampliﬁcation
HCV RNA was  extracted from plasma and serum samples using
the Abbott extraction method, and the 5′NCR region was  ampliﬁed
using an in-house method as described by Daniel et al.20 The DBS
were extracted and ampliﬁed as described in Bennett et al.21
3.7. Statistical analysis
Exact conﬁdence intervals calculated from the binomial dis-
tribution. The difference in AI values between plasma and DBS
samples was assessed using the Wilcoxon signed rank test for
paired data.
4. Results
4.1. HCV avidity test on plasma
Initially, the plasma samples were all diluted 1/400. The mean
AI for groups 1 (relating to acute infection), 2 (chronic) and 3
(resolved) were 8 (range 2–15), 91 (range 25–100), and 48 (AI
range 7–100), respectively (Table 2). The low AI generated among
the resolved infections indicated that this group could be mistaken
for recent infection. The samples from group 3 were then diluted
1/100 which generated an increase in the AI: mean AI increased
to 72 (range 21–100). Therefore, by diluting group 3 initially by
1/400 and then re-diluting the samples when the AI < 30 the mean
AI became 56 (range 21–100) for this group. Two way comparisons
between the 3 distributions (acute, chronic and resolved) were all
signiﬁcant (p < 0.0001). The two  lowest avidity indices from group
Table 2
Avidity results on plasma samples from individuals with acute (group 1), chronic (group 2) and resolved (group 3) infection.
Group 1 (recent) Group 2 (chronic) Group 3 (resolved)
Dilution 1/400 1/100 1/400 1/400 and 1/100a 1/400 1/400 and 1/100a
Number of samples 19 12 300 300 82 82
Mean avidity index
(%) (range)
8 (2–15) 13 (2–28) 91 (25–100) 91 (35–100) 48 (7–100) 56 (21–100)
Avidity index (%):
0–10
17 6 0 0 3 0
11–20  2 4 0 0 12 0
21–30  0 2 2 0 14 6
31–40 0 0 6 6 11 9
41–50 0 0 10 10 7 6
51–60 0 0 13 14 12 6
61–70 0 0 12 12 4 11
71–80 0 0 8 8 4 5
81–90 0 0 26 27 4 9
91–100 0 0 223 223 11 30
a Samples with AI values ≤ 30, with dilution 1/400, were retested using 1/100 dilution.
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Plasma (diluted 1/400)
DBS (diluted 1/240)
Avidity ≤ 30
Plasma diluted 1/100
DBS diluted 1/74
Recently infected, 
within past 4 - 5 
months
PCR positive PCR negative
Avidity ≤ 30 Avidity > 30
Avidity > 30
Chronic 
infection 
Reso lved infection Either recent or 
resolved infection;   
follow -up sample is 
required
Wash buffer treated plasma sampl e OD>1.0
Wash buffer treated DBS sampl e OD>1.0
YES
Unable to 
test
NO
PCR positive PCR negative
Reso lved 
infection 
Fig. 2. HCV avidity assay algorithm for testing plasma and DBS on HCV antibody positive individuals.
2 (chronic) – with AI of 25 and 30 – were retested at a 1/100 dilution
and produced an AI of 60 and 85, respectively. The genotypes for
these 2 discrepant chronic samples were genotype 2 and 3. When
12 samples from group 1 (insufﬁcient sample was available to test
all 19) were re-tested at a dilution of 1/100, the AI remained below
30 (mean AI 13, range 2–28). Based on the above results, the AI
cut-off was set at ≤30 and an algorithm for HCV avidity testing was
deﬁned (Fig. 2).
Applying the algorithm outlined in Fig. 2, the sensitivity of the
avidity test to detect recent infection on plasma was  100% (CI
82.4–100%); based on the 19 (PCR positive) acute infected samples
having all tested below the AI cut-off of 30. The speciﬁcity of the
avidity test was calculated as 99.3% (CI 97.6–99.9%); based on 298
of 300 chronic infected samples having tested above the AI cut-off
of 30.
Five patients from group 1 had follow up samples. Patient 1 had
an AI = 6, the follow up sample 11 days later was AI = 9. Thirteen days
after an initial-anti-HCV positive result, patient 2 had an AI < 10.
The AI increased to 15 on day 65 post initial anti-HCV positive test.
Patient 3 was  AI = 8, 74 days after the initial positive antibody result
(insufﬁcient sample to test original antibody positive sample), 13
days later the AI had increased to 81 (total of 87 days post 1st anti-
HCV positive result). Patients 4 and 5 were renal patients, infected
with HCV during an outbreak in a renal dialysis unit with the AI
monitored over sequential samples (Table 4). Patient 4 and 5 had
an AI ≤ 30 up to ∼124 days (4.1 months) and 96 days (3.2 months),
respectively post ﬁrst HCV PCR positive sample.
Two seroconverter panels were tested with the HCV avidity
assay (Table 3). For panel PHV901, the avidity index remained low
(≤30) on plasma up to 74 days (2.4 months) post their ﬁrst HCV
PCR positive result, and then increased above 30 at 101 days (3.3
months). For panel PHV917, the avidity index remained low (≤30)
on plasma up to 132 days (4.3 months) since their ﬁrst HCV PCR
positive result was  detected.
Table 3
Avidity results on 2 seroconverter panels: (a) PHV901 and (b) PHV917. Samples with AI < 10 indicate that the antibody level was detected on the kit wash buffer sample but
not  detected on the urea treated sample, indicating early infection. There were 3 wash buffer treated mock DBS in PHV917 that had an antibody level < 1.0 (low on table).
(a) PHV901 (b) PHV917
Sample Bleed dates Days since
ﬁrst PCR+
Antibody AI Sample Bleed dates Days since
ﬁrst PCR+
Antibody AI
Blood Mock DBS Blood Mock DBS
1 23/09/1993 Pre PCR+ N N N 1 29/05/1996 Pre PCR+ N N N
2  27/11/1993 0 N N N 2 18/06/1996 0 N N N
3  29/12/1993 32 P AI < 10 8 3 20/06/1996 2 N N N
4 31/12/1993 34 P AI < 10 7 4 22/08/1996 65 P AI < 10 AI < 10
5  05/01/1994 39 P AI < 10 7 5 07/10/1996 111 P AI < 10 Low
6  07/01/1994 41 P AI < 10 6 6 11/10/1996 115 P AI < 10 Low
7 01/02/1994 66 P 9 9 7 14/10/1996 118 P AI < 10 Low
8  09/02/1994 74 P 8 9 8 22/10/1996 126 P 10 12
9 08/03/1994 101 P 33 27 9 28/10/1996 132 P 9 8
10  14/04/1994 138 P 84 66
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Table 4
Avidity results for 2 renal dialysis unit patients. HCV transmission occurred during September 2010 for patient 4 while transmission for patient 5 occurred prior to June 2010.
(a) Patient 4 (b) Patient 5
Sample Date sample
collected
Days since ﬁrst
PCR+ result
Anti-HCV
(S/Co)b
AIBlood Sample Bleed dates Days since ﬁrst
PCR+ result
Anti-HCV
(S/Co)b
AIBlood
1 25/11/2010 72a 2.36 AI < 10 1 03/06/2010 0 0.06 NT
2  30/11/2010 77 2.89 AI < 10 2 06/09/2010 96 11.18 15
3 15/12//2010 92 15.05 5 3 14/09/2010 104 13.31 46
4 05/01/2011 103 16.09 6 4 11/10/2010 120 12.65 62
5  10/01/2011 108 14.30 6 5 19/10/2010 128 12.39 85
6  24/01/2011 124 11.77 21 6 02/11/2010 142 14.41 100
7  31/01/2011 131 13.02 45
8  04/02/2011 135 15.17 54
9 08/03/2011 167 15.00 83
a Approximate number of days since the patient was  HCV PCR positive-based on date of suspected transmission and 4 weeks to become PCR positive.
b Anti-HCV was  detected by Abbott Architect with S/Co > 1 positive.
Based on the serial samples shown in Tables 3 and 4, and patient
3 we estimate the window period for detecting a recent infection
with this HCV avidity assay (following a PCR positive result) is
approximately 3–4 months. Given the time from infection to detec-
tion of HCV RNA can be between 1 and 4 weeks, the assay identiﬁes
individuals who have become infected within the past 4–5 months.
4.2. HCV avidity test on DBS
DBS made from the plasma of 12 group 1 (recent), 50 group 2
(chronic) and 25 group 3 (resolved) samples were tested for avid-
ity, and results compared with those from the plasma samples
(Fig. 3). For the recent cases, there was no signiﬁcant difference
in AI results between plasma and mock DBS (mean/median dif-
ference: −0.4/0, p = 0.7); and all of the mock DBS samples had an
AI ≤ 30. For the chronic cases, the AI results on mock DBS were
signiﬁcantly lower than those found on plasma (mean/median dif-
ference: −9.3/−4, p < 0.0001); the majority (98%; 49/50) of the mock
DBS samples however had an AI > 30. The one chronic sample with
AI = 27 on DBS was retested at 1/74 dilution (Fig. 1) and the AI
became 42. This mock DBS was made from a plasma sample with
AI of 35.
For the resolved group 3, samples for mock DBS were cho-
sen with AI values on plasma ranging from 15 to 100 on initial
testing with dilution 1/400; ﬁve plasma samples had AI ≤ 30, but all
increased above this threshold with dilution 1/100 (Fig. 2). When
the mock DBS were diluted 1/240, there were 2 samples that were
antibody negative and 2 that had weak reactive antibody (Fig. 1). Of
the remaining 21 resolved DBS samples, 43% (9/21) had an AI ≤ 30
with dilution 1/240, but this reduced to 19% (4/21) with dilution
1/74 (Fig. 2).
Samples from the seroconverter panels PHV901 and PHV917
were also made into mock DBS (Table 3). For panel PHV901, at 101
days (3.3 months) after the ﬁrst PCR positive sample, the mock DBS
had an AI = 27 (below the cut-off and thus still indicating recent
infection), whereas the plasma sample had an AI = 32 (above the
cut-off and thus no longer indicating recent infection).
The majority (98%, 64/65) of group 4 chronic cases had an AI > 30
on DBS, with dilution 1/240. The one chronic case with an initial AI
of 27 (below the threshold) on DBS increased to an AI of 37 on re-
testing with dilution 1/74. Applying a dilution of 1/74 for initially
low AI (≤30) cases as outlined in the algorithm (Fig. 2), 90% (61/68)
of DBS samples in the resolved group 5 generated AIs above the 30
cut-off.
Based on the results from the 12 acute mock DBS samples, the
sensitivity of the HCV avidity test on DBS was  estimated at 100%
(95% CI 73.5–100%). Combining the results from the 50 chronic
mock DBS samples with the 65 chronic cases in group 4, the
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Fig. 3. Comparison of avidity index (AI) results on paired plasma and mock DBS samples from individuals with acute, chronic and resolved HCV infection*. *Dilutions used
were  1/400 for plasma and 1/240 for DBS; for samples with low AI (≤30) and PCR negative on initial testing, dilutions used were 1/100 for plasma and 1/74 for DBS.
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Table 5
Variability of the HCV avidity assay using both plasma and mock DBS tested on separate runs over a period of time. The mean AI and standard deviation of each sample is
shown in table.
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10
Sample type Plasma Plasma Plasma Plasma Plasma Mock DBS Mock DBS Mock DBS Mock DBS Mock DBS
Original AI 10 15 30 31 100 27 28 29 31 35
Number of times tested 40 6 7 6 40 5 3 3 3 3
Mean  AI 10 11 30 30 97 25 29 27 29 30
St  Dev 2.0 2.4 3.6 1.4 3.5 1.5 0.5 2.2 1.7 3.7
speciﬁcity of the avidity test on DBS was estimated at 98.3% (CI
93.9–99.8%), based on the algorithm given in Fig. 2.
4.3. Inter-test variability
Five plasma and 5 mock DBS samples were repeat tested on
different runs to measure the inter-test variablity (Table 5). Two
plasma samples were from acutely infected and 1 plasma sample
was from a chronic patient. The remaining 7 samples were orig-
inally found to be near or on the AI cut-off of 30. Variability was
consistent across the range of the test.
5. Discussion
This study has demonstrated that the avidity test in combina-
tion with PCR can differentiate between acute, chronic and resolved
infection HCV infection. This supports the ﬁndings of other papers
that have reported avidity testing for HCV. It can be difﬁcult to draw
conclusions and comparisons from various avidity tests when dif-
ferent methods or DA are used.13,22 However our study and those
of previous HCV avidity studies indicate that to determine an acute
HCV infection a supplemental test is required for accurate diag-
nosis when a negative anti-HCV sample is not available prior to
ﬁrst anti-HCV positive result.16,19,23 Previous studies have found
that patients with resolved HCV infection can have a lower avidity
index compared to chronic patients whose antibodies are continu-
ally exposed to the HCV virus.16–19
A testing algorithm has been developed for HCV avidity using
either plasma or DBS. In our laboratory we found that two dilu-
tion factors were required to help differentiate between chronic
and resolved infections when the sample had an AI < 30 and was
PCR negative. This is because adequate antibody must be present
to allow an accurate measurement of OD prior to treatment with
a DA.13,15,16 The dilution factors used may  vary in different lab-
oratories depending on the saturation point of the plate reader.
Samples with a recent infection retain the low avidity result but
samples from resolved infections showed the avidity increased
when a lower dilution factor was used.
In the seroconverter panel, one plasma sample had AI = 32 but
the mock DBS of this sample had AI = 27. This discrepancy can be
explained by the inter-test variability around the AI cut-off. This
suggests a grey zone range around the cut-off that would require
repeat testing and a follow up sample.
Though the majority of recently acquired HCV infections will
be PCR positive a small number may  be negative due to ﬂuctuating
virus levels or rapid clearance of the virus and so a follow up sample
would counter act any negative PCR results in recent infections. This
has been incorporated into the algorithm for HCV avidity testing.
Antibody maturation and consequently progression from low
avidity to high avidity is not always uniform. Various HCV
studies have indicated the variability in individual antibody
maturation.15,16 Many factors have been found to inﬂuence the
progression from low to high avidity.23–26 A low avidity result
with the assay described in this paper suggested that a recent HCV
infection has occurred within ∼4–5 months. In this study, group 1
(acute patients) were deﬁned as becoming anti-HCV positive after a
previous negative result taken 4–6 months ago. HCV antibodies can
take up to 8 weeks to develop and therefore increase the time for 1st
positive anti-HCV by at least 2 months. Two  of the patients that had
been used to estimate the recency were undergoing renal dialysis.
Renal dialysis patients can have altered antibody development.11
The HCV avidity assay used in this study was  a modiﬁcation
of a commercial assay that consisted of a mixture of HCV struc-
tural and non structural proteins. With these assays there is the
potential to be monitoring antibodies of different avidities to differ-
ent HCV antigens. A technique to differentiate between acute and
chronic infection using individual HCV antigens has recently been
described.27 HIV avidity has been shown to be affected by subtype
differences and this may  also affect the HCV avidity tests.28
The limitation of the current work was the number of samples
from recently infected individuals; this was reﬂected in the conﬁ-
dence intervals. A larger project using more samples and follow up
samples from known recently infected cohorts is planned. It would
also be of beneﬁt to obtain actual DBS and plasma samples at the
same time from patients; this would allow DBS, plasma and mock
DBS all to be monitored from an identical time point.
This paper shows that avidity testing can be used on DBS which
will not only enhance HCV surveillance but will be a useful tool in
identifying individuals who would beneﬁt from early HCV treat-
ment.
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